Gail Boxer Marcus Sells 2,212 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 2,212 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the transaction, the director now owns 19,386 shares in the company, valued at approximately $3,073,262.58. This trade represents a 10.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Natera Trading Down 3.3 %

Shares of NTRA stock opened at $146.06 on Friday. Natera, Inc. has a fifty-two week low of $52.01 and a fifty-two week high of $167.79. The stock’s fifty day moving average price is $127.38 and its two-hundred day moving average price is $115.61. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.01 and a current ratio of 4.39. The company has a market cap of $19.28 billion, a PE ratio of -82.99 and a beta of 1.53.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same quarter in the previous year, the firm earned ($0.95) earnings per share. The business’s quarterly revenue was up 63.9% on a year-over-year basis. Equities analysts predict that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on NTRA shares. Canaccord Genuity Group upped their target price on Natera from $150.00 to $165.00 and gave the company a “buy” rating in a research report on Wednesday. UBS Group lowered their price objective on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Leerink Partners boosted their target price on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. raised their price target on shares of Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Stephens reissued an “overweight” rating and issued a $125.00 price objective on shares of Natera in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $137.65.

Institutional Trading of Natera

A number of hedge funds have recently added to or reduced their stakes in NTRA. Geode Capital Management LLC lifted its stake in shares of Natera by 7.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock valued at $265,747,000 after acquiring an additional 143,825 shares during the last quarter. M&T Bank Corp raised its position in Natera by 7.9% in the third quarter. M&T Bank Corp now owns 5,513 shares of the medical research company’s stock valued at $699,000 after purchasing an additional 405 shares during the last quarter. Gordian Capital Singapore Pte Ltd boosted its stake in shares of Natera by 211.5% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 8,193 shares of the medical research company’s stock valued at $1,040,000 after purchasing an additional 5,563 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of Natera during the third quarter worth about $1,267,000. Finally, MML Investors Services LLC raised its holdings in Natera by 34.6% in the 3rd quarter. MML Investors Services LLC now owns 4,593 shares of the medical research company’s stock valued at $583,000 after buying an additional 1,180 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.